Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. B & B Pharmaceuticals, Inc.
WARNING LETTER
•B & B Pharmaceuticals, Inc.•October 30, 2018

B & B Pharmaceuticals, Inc. – FDA Warning Letter, Oct 30, 2018

Record Details

The FDA inspected B&B Pharmaceuticals, Inc. (FEI 3000719772) in Englewood, Colorado, from October 17-30, 2018, identifying significant Current Good Manufacturing Practice (CGMP) deviations for Active Pharmaceutical Ingredients (API). This renders their API adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Quality Unit (QU) Failures:** The QU failed to thoroughly investigate complaints (e.g., subpotent progesterone and meperidine, particle size issues) and did not determine root causes or routinely notify original API manufacturers. The QU also failed to adequately review batch records for completeness and accuracy, missing discrepancies and lacking signatures. Additionally, QU personnel were not independent of production operations. 2. **Cleaning Validation:** The firm failed to conduct adequate cleaning validation studies for non-dedicated equipment to prevent cross-contamination, especially for highly potent drugs. A 2008 study from a different location was deemed insufficient. 3. **Certificates of Analysis (COA):** B&B Pharmaceuticals omitted the name and address of original API manufacturers on COAs issued to customers and did not include copies of original batch certificates, compromising supply chain accountability.

The FDA found the company's November 2, 2018, response inadequate, particularly regarding the limited scope of

Company
B & B Pharmaceuticals, Inc.
Inspection date
October 30, 2018
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
People
  • Steven E. Porter (Program Division Director)
  • Rafael Padilla (Compliance Officer-Medical Devices)
View Company Profile

ID · 0eafe381-a034-40e3-9de8-c0e8891f2a11

Violation Codes6
21 U.S.C. 360(j)21 U.S.C. 331(p)21 U.S.C. 352(o)21 CFR 21021 CFR 21121 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for B & B Pharmaceuticals, Inc.
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore B & B Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.